↓ Skip to main content

Dove Medical Press

Drug delivery in overcoming the blood–brain barrier: role of nasal mucosal grafting

Overview of attention for article published in Drug Design, Development and Therapy, January 2017
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age
  • Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter
2 X users
facebook
1 Facebook page

Readers on

mendeley
92 Mendeley
Title
Drug delivery in overcoming the blood–brain barrier: role of nasal mucosal grafting
Published in
Drug Design, Development and Therapy, January 2017
DOI 10.2147/dddt.s100075
Pubmed ID
Authors

Carlotta Marianecci, Federica Rinaldi, Patrizia Nadia Hanieh, Luisa Di Marzio, Donatella Paolino, Maria Carafa

Abstract

The blood-brain barrier (BBB) plays a fundamental role in protecting and maintaining the homeostasis of the brain. For this reason, drug delivery to the brain is much more difficult than that to other compartments of the body. In order to bypass or cross the BBB, many strategies have been developed: invasive techniques, such as temporary disruption of the BBB or direct intraventricular and intracerebral administration of the drug, as well as noninvasive techniques. Preliminary results, reported in the large number of studies on the potential strategies for brain delivery, are encouraging, but it is far too early to draw any conclusion about the actual use of these therapeutic approaches. Among the most recent, but still pioneering, approaches related to the nasal mucosa properties, the permeabilization of the BBB via nasal mucosal engrafting can offer new potential opportunities. It should be emphasized that this surgical procedure is quite invasive, but the implication for patient outcome needs to be compared to the gold standard of direct intracranial injection, and evaluated whilst keeping in mind that central nervous system diseases and lysosomal storage diseases are chronic and severely debilitating and that up to now no therapy seems to be completely successful.

X Demographics

X Demographics

The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 92 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 92 100%

Demographic breakdown

Readers by professional status Count As %
Student > Master 13 14%
Researcher 11 12%
Student > Ph. D. Student 11 12%
Student > Bachelor 10 11%
Student > Postgraduate 6 7%
Other 13 14%
Unknown 28 30%
Readers by discipline Count As %
Pharmacology, Toxicology and Pharmaceutical Science 18 20%
Biochemistry, Genetics and Molecular Biology 9 10%
Agricultural and Biological Sciences 9 10%
Engineering 7 8%
Neuroscience 5 5%
Other 16 17%
Unknown 28 30%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 19 August 2020.
All research outputs
#16,868,837
of 25,584,565 outputs
Outputs from Drug Design, Development and Therapy
#1,010
of 2,254 outputs
Outputs of similar age
#256,370
of 422,901 outputs
Outputs of similar age from Drug Design, Development and Therapy
#18
of 30 outputs
Altmetric has tracked 25,584,565 research outputs across all sources so far. This one is in the 32nd percentile – i.e., 32% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,254 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.3. This one has gotten more attention than average, scoring higher than 51% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 422,901 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 36th percentile – i.e., 36% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 30 others from the same source and published within six weeks on either side of this one. This one is in the 40th percentile – i.e., 40% of its contemporaries scored the same or lower than it.